Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

"Being linked to 'Ozempic face' inducing changes to the mouth, teeth, gums and surrounding facial structures due to the rapid ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for “Ozempic” — marking a fundamental shift in how patients ...